Dr Pachmann’s maintrac® is a blood test that allows us to detect cells which have left the tumor and entered the bloodstream. Some of these circulating (epithelial) tumor cells (CETCs / CTCs) may be responsible for metastases (metastatic spread) occurring, and thus responsible for further progression of the disease.

Using the maintrac® cell count, the extent to which a treatment is proving successful can be monitored. For this assessment, the number of circulating cells is determined before therapy starts, and is compared with the number of cells over the course of therapy. The resulting progression of results gives an indication of whether cells are being destroyed by the cancer therapy.

maintrac® helps patients find a unique, personalised therapy, allowing for the success of the therapy to be monitored.

Service provider:
Dr. U. Pachmann Laboratory

Responsible person of contact:
Chief physician, Dr. med. Ulrich Pachmann, Doctor of Transfusion medicine